Similar to the present results, a previous study evaluating the activity of proteasome inhibitors in BRAF V600E mutant colorectal cancer models also demonstrated that BRAF mutant cells were preferentially sensitive to treatment with proteasome inhibitors compared to BRAF wild-type cells [24]. The gene discussed is BRAF; the disease is colorectal cancer.